BERKELEY, Calif., and VANCOUVER, British Columbia, December 24, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that its Board of Directors has approved a consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on …
BERKELEY, Calif., and VANCOUVER, British Columbia, December 17, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces its attendance and presentation scheduled at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the …
Safety and early efficacy data were presented on December 12th at 6:00 p.m. ET from the clinical trials of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: • Continued additive or synergistic activity observed in combination study of Bria-IMT™ with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.) as evident by tumor shrinkage …
Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: • Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.); • Bria-IMT™ in combination with INCMGA00012 (by Incyte Corporation). BERKELEY, Calif., and VANCOUVER, British Columbia, November 12, 2019 — BriaCell …
BERKELEY, Calif., and VANCOUVER, British Columbia, October 24, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all matters addressed at the special meeting (the “Meeting“) of the holders of common shares (the “Common Shares“) …
BERKELEY, Calif., and VANCOUVER, British Columbia, October 15, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has closed its previously-announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company. Under the Offering, …
BERKELEY, Calif., and VANCOUVER, British Columbia, October 8, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed on SEDAR an amendment to its management information circular dated September 23, 2019 (the “Circular”) to amend the maximum …
• Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell’s lead candidate, Bria-IMT™ in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer. • Cancer blocks the immune system preventing it from fighting and destroying cancer cells. Bria-IMT™ activates the immune system to fight and eliminate …
BERKELEY, Calif., and VANCOUVER, British Columbia, October 1, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announced on August 23, 2019 that it will hold a special meeting of shareholders on October 22, 2019 (the “Meeting”). The Company would like …
BERKELEY, Calif., and VANCOUVER, British Columbia, October 1, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer. October is Breast Cancer Awareness Month, an annual campaign to increase awareness of the disease. Significant progress has been made in breast cancer …